Overview

A Long-Term Study of JNS007ER in Patients With Schizophrenia

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety of JNS007ER 3-12 mg once daily in patients with schizophrenia over a long term period.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.
Treatments:
Paliperidone Palmitate